SAN DIEGO, February 5, 2021 – Today, Primmune Therapeutics announced the appointment of Rich Daniels as Chief Operating Officer, Scott Zook as Senior Vice President, Global Manufacturing and Randy Adams as Senior Advisor, Commercial Development. “The appointments of...
Financing co-led by seasoned healthcare investors, CAM Capital and Polaris Partners SAN DIEGO, October 27, 2020 — Primmune Therapeutics today announced the initial closing of a $27.4 million Series A financing to advance the development of novel...
SAN DIEGO, March 31, 2020 – Primmune Therapeutics announced today that it has selected PRTX007 as its lead clinical development candidate for SARS-CoV-2 (the virus that causes COVID-19) and for oncology indications. “PRTX007 is an oral small molecule that specifically...
SAN DIEGO, March 2, 2020 – Primmune Therapeutics today announced that it has raised $7 million in seed financing to support the development of novel orally-administered, small molecule toll-like receptor 7 (TLR7) agonists for long-term systemic activation of innate...
SAN DIEGO, November 6, 2019 – Primmune Therapeutics today announced that it will present primate pharmacology data on PRX034 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2019 in National Harbor, MD. PRX034 is a novel orally bioavailable small...
SAN DIEGO, April 1, 2019 – Primmune Therapeutics today announced that it will present preclinical data on a novel series of toll-like receptor 7 (TLR7) agonists engineered for systemic activation of innate immunity at the American Association for Cancer Research...
We use cookies to improve your experience on the Primmune website. By continuing to use our site, you agree to our use of cookies. Learn More
